Rx Product News (March 2018)

Pharmacy Times, March 2018 Central Nervous System, Volume 84, Issue 3

Rx products featured in the March 2018 issue of Pharmacy Times.

Sanofi

INDICATION: The FDA has approved Admelog, a rapid-acting insulin similar to Humalog, for use to improve blood sugar control in adults with type 2 diabetes and adults and children 3 years and older with type 1 diabetes.

DOSAGE FORM: Injection: 100 units/mL

FOR MORE INFORMATION: sanofi.us.com

AstraZeneca

INDICATION: The FDA has approved the expanded use of olaparib (Lynparza) tablets to include the treatment of patients with certain types of breast cancer that have spread and whose tumors have a specific inherited genetic mutation.

DOSAGE: Dosage Form: Tablets: 150 mg, 100 mg

FOR MORE INFORMATION: astraZeneca.com

Synergy Pharmaceuticals

INDICATION: The FDA has approved plecanatide (Trulance) for a second indication to include the once-daily treatment of irritable bowel syndrome with constipation in adults. Plecanatide is already approved for the treatment of adults with chronic idiopathic constipation.

DOSAGE: Tablet: 3 mg

FOR MORE INFORMATION: synergypharma.com

XGEVAMANUFACTURED BY: Amgen

INDICATION: The FDA has approved Amgen’s supplemental Biologics License Application for denosumab (Xgeva) to expand the approved indication for the prevention of skeletal-related events in patients with bone metastases from solid tumors to include patients with multiple myeloma.

DOSAGE: Injection: 120 mg/1.7 mL solution

FOR MORE INFORMATION: amgen.com